Global /United States /Healthcare /Drug Manufacturers - Specialty & Generic /NAGE
chevron_leftBack
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc.

NAGE
NASDAQ: NAGE Delayed
4.77USD -1.6%
As of 13 June 2026, Niagen Bioscience, Inc. has a market cap of $382.38M USD, ranking #16986 globally and #2853 in the United States. It ranks #1536 in the Healthcare sector, and #84 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
16986
Country Rank
2853
Sector Rank
1536
Industry Rank
84
Key Stats
Market Cap
$382.38MUSD
Enterprise Value
$314.94MUSD
Revenue (TTM)
$129.42MUSD
EBITDA (TTM)
$15.08MUSD
Net Income (TTM)
$17.38MUSD
EBITDA Margin
12%
Profit Margin
13%
PE Ratio
23.8
Forward PE
18.6
PS Ratio
2.9
PB Ratio
5.1
EV/EBITDA
20.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Robert Fried open_in_new
Employees
117
Founded
1999
Website
niagenbioscience.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.6% -0.4% 12% -22% -35% -38%

News

Loading...

NAGE Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
NAGE
Niagen Bioscience Inc
ISIN: US1710774076
Shares Out.:
79.644M1 Shares Float: 52.486M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
4.77 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Niagen Bioscience, Inc.

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (United States)
Name
Market Cap diff.
PE
$29.56B
8K%
-
INDV
$2.07B
1.54B GBP
441%
-
NDOI
$1.8B
371%
0.4
$1.76B
361%
-
$1.33B
247%
-
$1.02B
168%
12.1
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$36.75B
108.92B ILS
10K%
24.2
$15.84B
107.34B CNY
4K%
16.0
CIPLA
$11.16B
1.06T INR
3K%
23.4
LUPIN
$11.04B
1.05T INR
3K%
22.7
$9.09B
61.6B CNY
2K%
80.6
$8.74B
7.57B EUR
2K%
-
chevron_leftBack